Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-episode schizophrenia. A Clinical Perspective

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001662" target="_blank" >RIV/65269705:_____/12:#0001662 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14740/12:00059859

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2012/764769" target="_blank" >http://dx.doi.org/10.1155/2012/764769</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2012/764769" target="_blank" >10.1155/2012/764769</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-episode schizophrenia. A Clinical Perspective

Popis výsledku v původním jazyce

Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal data available is limited, many experts recommend prescribing long-acting injectable second-generation antipsychotics (mostly risperidone or alternatively paliperidone) in the early stages of schizophrenia, particularly in patients who have benefited from the original oral molecule in the past and agree to receive long-term injectable treatment. Early application of long-acting injectable second-generation antipsychotics can significantly reduce the risk of relapse in the future and thus improve not only the social and working potential of patients with schizophrenia but also their quality of life.

Název v anglickém jazyce

Role of Long-Acting Injectable Second-Generation Antipsychotics in the Treatment of First-episode schizophrenia. A Clinical Perspective

Popis výsledku anglicky

Approximately 80% of patients with the first-episode schizophrenia reach symptomatic remission after antipsychotic therapy. However, within two years most of them relapse, mainly due to low levels of insight into the illness and nonadherence to their oral medication. Therefore, although the formal data available is limited, many experts recommend prescribing long-acting injectable second-generation antipsychotics (mostly risperidone or alternatively paliperidone) in the early stages of schizophrenia, particularly in patients who have benefited from the original oral molecule in the past and agree to receive long-term injectable treatment. Early application of long-acting injectable second-generation antipsychotics can significantly reduce the risk of relapse in the future and thus improve not only the social and working potential of patients with schizophrenia but also their quality of life.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FL - Psychiatrie, sexuologie

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Schizophrenia Research and Treatment

ISSN

2090-2085

e-ISSN

—

Svazek periodika

2012

Číslo periodika v rámci svazku

764769

Stát vydavatele periodika

EG - Egyptská arabská republika

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—